MDS

Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.

Advertisement
Advertisement
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 30, 2024
HMAs, either as monotherapy or in combination with venetoclax, represent the standard of care for higher-risk MDS or AML.
Leah LawrenceMeeting News | December 27, 2024
According to a study, patients with MDS and CMML have dismal clinical outcomes after failure of HMA therapy.
Leah LawrenceMeeting News | December 27, 2024
Investigational combinations for MDS appeared to be well tolerated while triplets results in high-grade toxicity.
Esther OlivaMyelodysplastic Syndromes | December 27, 2024
An expert speak on site at ASH 2024 about the Health-related quality of life data from the phase 3 COMMANDS trial.
Leah LawrenceAcute Myeloid Leukemia | December 26, 2024
Phase 2 study results outline benefit of adding venetoclax to intensive chemo in MDS and AML patients.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Moving forward, prospective studies must validate these findings and refine risk stratification tools like the IPSS-R in MDS.
Blood Cancers Today Staff WritersMeeting News | December 24, 2024
Some patients with ZRSR2-mutated CCUS had concurrent blood cancers or disorders, and others had protective co-mutation.
Jamile Shammo, MDMyelodysplastic Syndromes | December 23, 2024
A discussion on the post hoc analysis on quality of life from the COMMANDS trial.
Thomas LeBlanc, MD, MAMyelodysplastic Syndromes | December 23, 2024
Discussing the COMMANDS trial and sequencing luspatercept in patients with myelodysplastic syndromes.
Thomas LeBlanc, MD, MAMyelodysplastic Syndromes | December 23, 2024
How to address ESA failure or ineligibility in patients with MDS...
Thomas LeBlanc, MD, MAMyelodysplastic Syndromes | December 23, 2024
Results from a real-world analysis of post-ESA treatment outcomes in patients with lower-risk myelodysplastic syndrome.
Patrick DalyMeeting News | December 20, 2024
Early signs of clinical activity have been shown in a phase I/II study of tagraxofusp/decitabine in MDS and CMML.
Patrick DalyMeeting News | December 20, 2024
Mature data of three immunotherapy-based hypomethylating agent combinations were presented at ASH.
Patrick DalyAcute Myeloid Leukemia | December 20, 2024
High complete response rates and low early mortality rates facilitate the majority of patients to allogeneic SCT.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
An ongoing phase 1 study is evaluating the safety and efficacy of danvatirsen through two substudies.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
New WHO and ICC 022 guidelines propose lowering the threshold for diagnosis of CMML.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
High-risk MDS is associated with poor outcomes, making the assessment of treatment response critical.
Blood Cancers Today Staff WritersMeeting News | December 20, 2024
A myelofibrosis cohort showed that tapering to achieve molecular remission helped promote OS after transplant.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
The design of a phase 3 trial of elritercept for transfusion-dependent anemia in lower-risk MDS was presented at ASH 2024.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
Increasing evidence suggests a connection between acquired somatic mutations and inflammatory processes in myeloid neoplasms.
Blood Cancers Today Staff WritersMeeting News | December 19, 2024
The clinical activity of vibecotamab in low-blast, high-risk myeloid neoplasms has been demonstrated in a phase II study.
Blood Cancers Today Staff WritersMeeting News | December 18, 2024
Somatic IDH1 mutations are present in approximately 3% of patients with MDS and are associated with poor prognosis.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | December 13, 2024
New research is offering new hope for these challenging case of MDS and sAML.
Blood Cancers Today Staff WritersMeeting News | December 13, 2024
Ivosidenib is a promising oral therapy for patients with IDH1-mutated MDS.
Blood Cancers Today Staff WritersMeeting News | December 12, 2024
Overall survival is improved in patients with SF3B1del5q-mutated MDS when lenalidomide is sequenced before luspatercept.
Blood Cancers Today Staff WritersMeeting News | December 12, 2024
Findings from a phase II trial study of patients with MDS highlight the clinical benefits and safety profile of enasidenib.
Blood Cancers Today Staff WritersMeeting News | December 12, 2024
Ceralasertib is a novel oral ataxia telangiectasia and Rad3-related inhibitor for patients with myelodysplastic syndromes.
Blood Cancers Today Staff WritersMeeting News | December 12, 2024
The presence of genetic mutations and specific cytopenias emerged as key predictors of progression in MDS.
Blood Cancers Today Staff WritersMeeting News | December 11, 2024
The phase 3 COMMANDS trial results underscore the potential longer-term clinical benefits of luspatercept in lower-risk MDS.
Blood Cancers Today Staff WritersMeeting News | December 30, 2024
Phase 2 results of AZA-VEN in acute myeloid leukemia shows an efficacy benefit.
Blood Cancers Today Staff WritersMeeting News | December 10, 2024
New findings underscore the potential of single-cell analyses in the unbiased unraveling of disease mechanisms in MDS.
Blood Cancers Today Staff WritersMeeting News | December 10, 2024
Results from the phase 1 Combala study show the benefit of luspatercept and erythropoiesis-stimulating agents in MDS.
Blood Cancers Today Staff WritersMeeting News | December 10, 2024
The phase 3 EPO-PRETAR trial demonstrates importance of early administration of ESAs in patients with MDS and anemia.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Tapotoclax was safe and may warrant consideration in combination with other therapies in MDS post-HMA failure.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
ESAs had a high rate of failure among patients with lower-risk MDS and often continued treatment despite failure.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Oral azacitidine plus cedazuridine achieved pharmacokinetic equivalence to subcutaneous azacitidine in MDS and MPN.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Retrospective analysis shows that AML treatment strategies are effective for patients with MDS or CMML with NPM1 mutations.
Andrew MorenoMyelodysplastic Syndromes | November 22, 2024
This type of intervention produced more favorable results in patients with either hematologic or pre-hematologic relapse.
Melissa BadamoMyelodysplastic Syndromes | November 22, 2024
High circular RNA abundance is correlated with disease progression in patients with MDS.
Andrew MorenoMyelodysplastic Syndromes | November 21, 2024
The favorable effects from vamifeport pharmacologic iron restriction were enhanced by combination with luspatercept.
Andrew MorenoMyelodysplastic Syndromes | November 21, 2024
The model's superior engrafting of HSPCs from patients with MDS brings better replication of the disease microenvironment.
Melissa BadamoMyelodysplastic Syndromes | November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
Is ESA use and performance in the academic setting reflective of real-world MDS practice? Our expert panel discusses.
Jamile Shammo, MDMyelodysplastic Syndromes | November 18, 2024
The panel discusses how to best implement such a monitoring system to address a widespread issue of suboptimal dosing.
Melissa BadamoMyelodysplastic Syndromes | November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
Jamile Shammo, MDMyelodysplastic Syndromes | November 15, 2024
The panel led by Jamile Shammo, MD, reacts to results from a claims database study comparing the agent with ESAs.
Melissa BadamoMyelodysplastic Syndromes | November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.